Posts tonen met het label Ataxia. Alle posts tonen
Posts tonen met het label Ataxia. Alle posts tonen

zaterdag 20 juli 2019

uniQure - gene therapy SCA3 mousemodel



uniQure is a leading gene therapy company advancing transformative therapies for patients with severe medical needs.

Spinocerebellar Ataxia Type 3, also known as Machado-Joseph disease, is caused by a CAG-repeat expansion in the ATXN3 gene that results in an abnormal form of the toxic protein ataxin-3, leading to brain degeneration that results in movement disorders, rigidity, muscular atrophy and paralysis.

The company has engineered an artificial microRNA candidate, AMT-150, to target the ataxin-3 gene in a SCA3 knock-in mouse model. 

An inactivated virus vector is used to deliver AMT-150 to the nerve cells. The virus containing AMT-150 is injected close to the cerebellum. 

The 6-week proof-of-concept study demonstrated that a single AMT-150 injection in the cerebrospinal fluid resulted in significant mutant ataxin-3 lowering at each of the primary sites of disease neuropathology, namely the cerebellum (up to 53%) and brainstem (up to 65%).

These results were corroborated by preclinical studies in human induced Pluripotent Stem Cell (iPSC)-derived neurons showing a dose-dependent lowering of ataxin-3 mRNA of up to 55%.

These studies further demonstrate the potential utility and safety profile of the miQURE™ technology, the Company’s proprietary gene-silencing platform.

“We believe that the data from these preclinical studies in the knock-in mouse model and in iPSC-derived neurons show the potential of AMT-150 to alter the course of this devastating disease after a single administration,” stated Sander van Deventer, M.D., Ph.D., chief scientific officer at uniQure.



---------------------------------------------------------------
Press release, 7 May 2019



zondag 21 april 2019

Cerebellum good for more than moving you around


The cerebellum has come a long way. Once relegated to a supporting role in regulating movement, an accumulating mass of evidence has put this small but mighty (it contains half of all the brain’s neurons) structure smack in the middle of a broad range of non-motor functions. Its disruptions have been implicated in neuropsychiatric ills from addiction to schizophrenia. Some research suggests a role in Alzheimer’s disease.






“It’s an integral part of the nervous system subserving sensation, cognition, emotion, and autonomic function,” says Jeremy Schmahmann, professor of neurology at Harvard.


In the motor control system, cerebellar function apparently involves a kind of fine-tuning that coordinates incoming and outgoing neural signals. In complex movements like running or jumping, for example, the body must sense and instantly reposition feet, knees and torso. The cerebellum quarterbacks the process based on learning and predicting what adjustments the task requires.


“We think it’s doing this same computation with all different behaviors, balancing not just movement and gait, but also cognitive control and emotional processing,” Schmahmann says. “An important function of the brain is to maintain the organism in a state of optimal interaction with its surroundings—family, community, the world at large. All require modulation around a baseline.”


A rewarding area


Anatomical research from the early ’80s and functional imaging in recent years have established cerebellar linkage to areas of the cerebral cortex activated by diverse cognitive and emotional tasks. But evidence of causation has been elusive. “There was no strong mechanistic framework to interpret those results,” says Kamran Khodakhah, chair of the Department of Neuroscience at Albert Einstein College of Medicine. 


A recent study in Khodakhah’s lab, reported in Science, took a big step in that direction. “Our work provides direct, unequivocal evidence that the cerebellum powerfully modulates a non-motor brain area,” he says. That happens to be the ventral tegmental area (VTA), a key part of the dopaminergic reward system central to conditioned learning, motivation, and social behavior.


The researchers genetically programmed cerebellar neurons with projections to the VTA to be activated or inhibited by pulses of light, an optogenetic technique. Stimulating the cerebellar neurons, they found, increased the firing rate of neurons in the VTA as well.


This activation had the effect of reward: by turning the cerebellar neurons on, the researchers induced the mice to prefer a randomly chosen area of the rodents’ cage. Repeated activation even conditioned them to opt for a bright vs. dark chamber—opposite their instinctive pattern.


Most intriguing was the effect on social behavior. When given the choice of entering an empty chamber or one occupied by another mouse, the rodents ordinarily prefer to spend their time in company. By silencing the cerebellar-VTA circuit optogenetically when the mice entered the social chamber, the researchers cancelled that preference. By selectively activating the circuit, they induced the mice to prefer the empty space.


“The study demonstrated that optogenetics can be “an enormously powerful tool in experimental and cognitive neuroscience,” Schmahmann says. “We, astonishingly, can modulate the behavior of an awake animal using these 21st century tools on a specific circuit—and that’s very cool. It’s a real step forward in experimental paradigm, not just for the cerebellum and VTA, but the cerebellum and all the other areas it’s connected to.”


Because conditioned learning and social behavior are central to a range of brain disorders, the reward circuitry explored in this paper could help explain the seeming ubiquity of the cerebellum in psychopathology. The connection is clearest, perhaps, in addiction.


“There is a wealth of indirect evidence that the cerebellum is part of addiction circuitry, and involved in addiction-altered functions such as decision-making, habit, and inhibitory control,” Marta Miquel, of Universitat Jaume I, Castellón de la Plana, Spain, said in an e-mail interview.


As reviewed in her 2016 paper, arguments for this proposition include anatomical links and the role of the cerebellum in forming and storing emotional memory. Molecular mechanisms of cerebellar plasticity are the target of addictive drugs, and altered synapses have been linked to drug dependence, tolerance, and withdrawal symptoms.


Craving is a defining symptom of addiction: repeated studies have shown the cerebellum to be strongly activated by drug cues (such as a syringe, for an IV user) in people with addictions, and linked the degree of activation with the intensity of craving.


The studies reported in the Khodakhah paper provide “a straightforward mechanism to understand cerebellar control in motivation and decision-making, and, more important, to explain how addictive drugs can alter these functions,” Miquel says.


“Addiction is a brain disorder that involves much more than dopamine,” she says, “but it is clear that drug-induced dopamine alterations are a crucial part of its physiopathology.”


Autism and beyond


Considerable research links the cerebellum with autistic spectrum disorders (ASD), says Catherine Stoodley of American University. “You see connections at every level of analysis: post-mortem studies, mouse models; in human neuroimaging [of ASD], cerebellar differences were one of the earliest findings.” 


Disrupted social behavior is a core feature of ASD, and the finding, in the Khodakhah research, that the cerebellum can directly modulate social reward, “is a compelling piece of the puzzle,” she says. The methodology is “very exciting: any time you can be specific about the circuits you’re targeting and modulating, it allows for a level of detailed understanding we couldn’t have just 10 years ago.”


Stoodley’s own research examines the cerebellum in another kind of detail. “It’s possible that regions within it are associated with different symptoms of autism.” she says. “Originally, associations with the repetitive motion aspect of autism got the most attention. Now, we see some of the most compelling evidence in the social cognition domain.” 


Both animal and human imaging data brought her attention to the Right Crus (RCrusI) area of the cerebellum, which has functional connectivity to cortical networks relevant to social processing and to ASD.


In a study reported in Nature Neuroscience, she and colleagues showed that this connectivity is disrupted in mouse models of ASD, and in children with the condition. When the researchers chemically inhibited RCrusI activity in normal mice, the animals demonstrated impaired social behavior in ways comparable to mouse models of ASD.


Most interesting of all, the researchers showed that chemically stimulating the RCrusI in an ASD mouse model restored functional connectivity between the cerebellum and the crucial part of the frontal cortex, and ameliorated ASD-type social deficits. The treatment “rescued” social behavior in the mice.


Might the cerebellum be a gateway to effective treatment for ASD? A feasible approach that Stoodley is already exploring involves transcranial brain stimulation.


The location of the cerebellum makes it highly accessible to these non-invasive techniques: direct current stimulation (tDCS) of the area has been used effectively for a movement disorder, dystonia; and transcranial magnetic stimulation (TMS) was shown in a 2010 study to improve symptoms of schizophrenia.


In the Nature Neuroscience paper, Stoodley and her colleagues showed that tDCS could alter cerebellar-cortex connectivity in neurotypical human subjects, and she has not-yet-published data on whether these changes influenced performance on social, language, and motor tasks.


She is collecting data on symptom modulation with tDCS in young adults with ASD. “We’re still exploring the basic science of the mechanism. There’s a suggestion of the potential for therapeutic application, but we need to do more of the basic research first.”


Kamran Khodakhah expresses similar cautious optimism. He plans to collaborate with psychiatric colleagues in testing TMS to reduce craving and prevent relapse in addicts—but only after several years of animal work exploring the cerebellar-reward circuit and social behavior in more detail.


Some of the most provocative—and speculative—research involves neurodegenerative disorders, including Alzheimer’s disease. “It’s very much a fringe conversation,” says Jeremy Schmahmann, “but I was struck by the literature, going back a long time, pointing to pathology in the cerebellum in AD.” The circuits that degenerate in AD “seem to include the cerebellum, … although the cerebellum itself is relatively spared by the disease.”


If its involvement proves to be meaningful here, “perhaps we can use the cerebellum to gain access to the system and improve damaged function in the cerebral hemispheres,” he says. 

---------------------------------------------------------------------------

The DANA Foundation, Article by Carl Sherman, April 3, 2019






zondag 6 januari 2019

Treatment with a dietary supplement for a rare ataxia: SCA38



Research presented at the International Ataxia Research Conference in September 2017 and published in a medical journal, highlights a treatment option for a very rare form of ataxia.

What causes SCA38?


A team at the University of Brescia in Italy found the gene causing SCA38 in three Italian families with late-onset, slowly progressive ataxia. Most of these patients also had nystagmus (involuntary eye movement), pes cavus (hollow foot sole) and a reduced sense of smell.


Following on from that discovery in 2014, the team studied the cellular mechanisms that cause the condition. The researchers found that SCA38 is caused by mutations in a gene called ELOVL5, which codes for an enzyme that makes polyunsaturated fatty acids, including one called docosahexaenoic acid (DHA). Usually, this enzyme is found in high levels, mostly in the cerebellum. In SCA38, however, the enzyme’s function is affected and might be harmful, as it reduces the levels of DHA.


This important discovery has led the team to carry out a treatment trial with 10 of their SCA38 patients, testing the effect of supplementing DHA (a dietary fatty acid supplement). The rationale for the trial is two-fold: firstly, to compensate for the reduction in DHA; secondly, because of the low level of DHA in SCA38, levels of the ELOVL5 enzyme are increased. This enzyme is the mutated, harmful version; therefore, increasing DHA levels should decrease the levels of the harmful ELOVL5 mutated protein.

Trial shows positive results 


A four-month, double-blind and placebo-controlled trial was performed in 10 people with SCA38 (five on treatment and five on placebo). This was followed by a 40-week period in which every participant took the DHA supplement. Results showed a statistically significant change in
the ataxia symptoms among the treatment group, as measured by the SARA ataxia rating scale (but not the ICARS rating scale), compared to the placebo group. The assessment made with the SARA and ICARS in the 40-week second phase also showed that there was a statistically significant difference between the scores at the start and at the end of the trial. The researchers also measured results by using a brain scanning technique, which reported a change in the cerebellum’s metabolism after the 40-week treatment, compared to baseline. There were no side effects reported.

Implications of the results 


Although the trial was very small, the lack of side effects and the fact that the treatment is an inexpensive dietary supplement which makes up for the insufficient natural levels, suggests that this could be a treatment option for neurologists to consider for SCA38 patients.


Lead researcher, neurologist Dr Barbara Borroni, told Ataxia UK: “All participants of the trial have chosen to continue taking the DHA supplementation after the trial ended and we are pleased with the continued improvement in their condition. At this stage we are not planning further trials but we would recommend any patients diagnosed with SCA38 to be treated with DHA under the supervision of their neurologist. Due to genetic screening being done in some hospitals in Italy, we are now aware of two further people having been diagnosed with SCA38 and treatment with DHA has been initiated.”

-------------------------------------------------------------

Ataxia UK magazine, 203, autumn 2018









zondag 30 december 2018

Using gene silencing to alleviate common ataxia


June 20, 2018


Michigan Medicine - University of Michigan


In what researchers are calling a game changer for future ataxia treatments, a new study showed the ability to turn down the disease progression of the most common dominantly inherited ataxia, Spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease.





Spinocerebellar ataxia type 3 (SCA3) affects about one in 20,000 people. There's no disease-modifying therapy available, and patients slowly progress to an early death. A single gene mutation causes this neurodegenerative disease, making it an ideal target for a group of University of Michigan researchers.


For this preclinical study published in the Annals of Neurology, University of Michigan researchers employed nucleotide-based gene silencing to target the SCA3 disease gene, ATXN3. They greatly reduced levels of the mutant RNA coded by the gene in a mouse model of the disease without any toxic effects.


"Recent advances in antisense oligonucleotide technology provided us with a great opportunity for therapeutic targeting ," says co-first author Hayley McLoughlin, Ph.D., research investigator in the U-M Department of Neurology. "Although we still don't yet know the exact point of no return for this disease, we know how to turn things down before the disease burden accumulates to the point of detriment."


After two treatments, McLoughlin says the mouse model, which normally replicates similar disease motor phenotypes, is completely rescued. Importantly, it's the first time this animal model has been corrected through any therapy and is substantial proof-of-concept for future human clinical trial preparation.


"These encouraging results move us one step closer to disease-slowing therapy for this fatal disorder," says senior author Henry Paulson, M.D., Ph.D., a U-M professor of neurology and director of the Michigan Alzheimer's Disease Center. "They also offer hope that similar approaches might work for a number of brain diseases caused by the deleterious action of specific disease genes."


Team awarded $2.15M


Next, the U-M team in collaboration with Ionis Pharmaceuticals will pursue final drug development with a new U01 grant from the National Institute of Neurological Disorders and Stroke, at the National Institutes of Health. The U01 CREATE Bio Optimization Track funds researchers' work on potential therapies with an end goal of nominating a clinical candidate.


----------------------------------------------------------------
Hayley S. McLoughlin, Lauren R. Moore, Ravi Chopra, Robert Komlo, Megan McKenzie, Kate G. Blumenstein, Hien Zhao, Holly B. Kordasiewicz, Vikram G. Shakkottai, Henry L. Paulson. Oligonucleotide therapy mitigates disease in Spinocerebellar Ataxia Type 3 mice. Annals of Neurology, 2018; DOI: 10.1002/ana.25264













maandag 24 december 2018

Abnormal eyeblink in preclinical SCA3 mutation carriers


Spinocerebellar ataxias (SCAs) are a group of autosomal dominantly inherited degenerative diseases. As the pathological process probably commences years before the first appearance of clinical symptoms, preclinical carriers of a SCA mutation offer the opportunity to study the earliest stages of cerebellar dysfunction and degeneration.


To study the earliest stages of cerebellar dysfunction an eye blink test is performed in 18 preclinical carriers of a SCA3 mutation and 16 healthy, age-matched controls. The participants were presented with repeated pairings of an auditory tone with a supraorbital nerve stimulus with a delay interval of 400 ms.


Preclinical carriers acquired significantly less conditioned eyeblink responses than controls and learning rates were significantly reduced. This motor learning defect was, however, not associated with the predicted time to onset.


Eye blink is impaired in preclinical carriers of a SCA3 mutation, as a result of impaired motor learning capacities of the cerebellum and is thus suggestive of cerebellar dysfunction. The eye blink test can be used to detect but probably not monitor preclinical cerebellar dysfunction in genetic ataxias, such as SCA3.

------------------------------------------------------------------------
Artikel








maandag 17 december 2018

IntraBio Receives Spinocerebellar Ataxia Orphan Drug Designation from the FDA






December 10, 2018


IntraBio Inc., a late-stage biopharmaceutical company developing novel therapies for rare ("orphan") and common neurodegenerative diseases, announced that the US Food and Drug Administration has granted Orphan Drug Designation (ODD) to its lead compound series (IB1000s) for the treatment of Spinocerebellar Ataxias (SCAs).


IntraBio has previously been granted Orphan Medicinal Drug Designation from the European Commission for IB1000s for the treatment of Spinocerebellar Ataxias.


"IntraBio's efforts to pursue a treatment for Ataxia is direly needed by the Ataxia patient population," National Ataxia Foundation’s (NAF) Medical Director, Susan Perlman, MD, said. "The Orphan Drug Designation of the IntraBio lead compound series (IB1000s) will accelerate development of this agent, which has potential symptomatic and neuroprotective activity for SCA and other Central Nervous System disorders. NAF supports IntraBio's efforts to offer the Ataxia community a treatment option that may alleviate some of their life-altering symptoms."


IntraBio has evaluated the effect of IB1000s in compassionate-use studies in over 175 patients, forming the scientific basis for IB1000s to be further investigated for the treatment of 18 indications, including hereditary ataxia.


IntraBio is currently in the process of applying for multi-national clinical trials with its lead asset (IB1001) for the treatment of certain inherited Cerebellar Ataxias.

----------------------------------------------------------









zaterdag 8 december 2018

Spinocerebellai ataxia 48 (SCA48)



A new spinocerebellar ataxia (SCA48) is characterized by early cerebellar cognitive-affective syndrome (CCAS) and late-onset SCA.


STUB1gene



A family has been followed for more than a decade with periodic neurologic and neuropsychological examinations. Whole exome sequencing was performed in 3 affected and 1 unaffected family member.


Six patients fully developed cognitive-affective and complete motor cerebellar syndrome associated with cerebellar atrophy. Three presymptomatic patients showed cerebellar atrophy cerebellum, suggesting that cerebellar atrophy preceded the ataxia, and that the neurodegeneration begins in cerebellar areas related to cognition and emotion, spreading later to the whole cerebellum.


This report describes a heterozygous STUB1 pathogenic genetic variant causing dominant cerebellar ataxia. 
---------------------------------------------------------------------

Source link


woensdag 5 december 2018

UniQure - gene therapy pipeline extended to SCA3


November 19, 2018


Lexington (MA, USA) and Amsterdam (Netherlands)


uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the expansion of its research pipeline with novel AAV gene therapy approaches to treating among others Spinocerebellar Ataxia Type 3 (SCA3) at the Company’s Research & Development Day held this morning in New York City.









“We are very proud of the progress the Company has made to deliver extensive preclinical data for these new gene therapy programs that expand our pipeline and further validate uniQure’s potential best-in-class vector delivery platform,” stated Sander van Deventer, M.D., Ph.D., chief scientific officer at uniQure. “The addition of these gene therapy candidates for indications in the liver and CNS brings us yet another step closer towards uniQure's goal of delivering transformational medicine to patients suffering from genetic diseases. We look forward to advancing these programs closer to the clinic in 2019.”


uniQURE introduced the new gene therapy candidate AMT-150 as a novel treatment for Spinocerebellar Ataxia Type 3 (SCA3), a central nervous system disorder.


AMT-150 is a one-time, intrathecally-administered, AAV gene therapy incorporating the Company’s proprietary miQURE™ silencing technology that is designed to halt ataxia in early manifest SCA3 patients.


In an in-vitro study with human Induced Pluripotent Stem (IPS) derived neurons, AMT-150 has been shown to lower the human ataxin-3 protein by 65 percent, without any off-target effects. The Company also performed a proof-of-concept in-life study in SCA3 mice demonstrating that AMT-150 was able to lower toxic ataxin-3 protein by 65 percent in the brain stem after a single administration. Further studies in non-human primates demonstrate the ability to distribute and express a reporter gene at a clinically relevant level in the most degenerated brain regions in SCA3.


These preclinical studies show that a single administration of AMT-150 results in sustained expression and efficient processing with on-target engagement. They also show that AMT-150 appears to be safe due to the lack of off-target activity.


The Company is currently performing studies in large animals to demonstrate further safety and efficacy.
-------------------------------------------------------------------------

Pressrelease








donderdag 29 november 2018

Spinocerebellar ataxia: imaging biomarkers



Currently, the most common clinical scores for rating the disease severity are the Scale for the
Assessment and Rating of Ataxia (SARA). However, the SARA score cannot be used to evaluate pre-manifest individuals and their small effect size would require large numbers of patients in clinical trials, which is an issue due to the scarcity of SCA.


As gene-based therapies are showing promise in preventing or reversing SCA pathophysiology, there is a need for biomarkers with effect sizes greater than clinical scores, which can be used in trials on small sample sizes.

Study


In the study a unique cohort of 57 patients with SCA1, SCA2, SCA3  and SCA7 and 24 healthy controls of similar age, sex and body mass index was enrolled. Longitudinal clinical and imaging data at baseline and follow-up (mean interval of 24 months) were collected.

Clinical scores worsened as atrophy increased over time. However, atrophy of cerebellum and pons showed very large effect sizes compared to clinical scores. Imaging was sensitive to microstructural cross-sectional differences that were not captured by conventional methods. Automated imaging also showed larger effect sizes than manual imaging.


Conclusion


This study showed that volumetry (imaging) outperformed clinical scores to measure disease progression in SCA1, SCA2, SCA3 and SCA7.


Therefore, the researchers advocate the use of volumetric biomarkers in therapeutic trials of autosomal dominant ataxias. In addition, automated imaging showed larger effect size than manual imaging to detect cross-sectional microstructural alterations in patients relative to controls.

-------------------------------------------------------------------------------------
Autosomal dominant cerebellar ataxias: Imaging biomarkers with high effect sizes, Isaac M. Adanyeguh et al., Neuroimage Clin. 2018; 19: 858–867.
Published online 2018 Jun 14. doi: 10.1016/j.nicl.2018.06.011








dinsdag 13 november 2018

Antisense oligonucleotides restore visual function in a mouse model of SCA7



Spinocerebellar ataxia type 7 (SCA7) is a genetic disorder caused by mutations in the ATAXIN-7 gene. SCA7 is characterized by impairments in coordination, balance, and speech and by retinal degeneration. Retinal degeneration results eventually in complete blindness.


Niu et al. developed a strategy for treating visual impairments in SCA7 by inhibiting the mutated Ataxin-7 in the retina using antisense oligonucleotides (ASOs).


To explain how this technique works, I start with our genes. Our genes are made out of DNA, a chemical code that includes the information that allows our cells to function. This information is used to make proteins, the molecular machines and building blocks that are crucial for cells to work. Antisense oligonucleotides intervene at a critical intermediate stage between DNA and proteins – where the DNA is converted into a molecule called messenger RNA (or mRNA for short). mRNA is very similar to DNA, but much less stable, and chemically very slightly different. It acts as the template for making proteins. If you can get rid of it, the proteins don’t get made. Antisense oligonucleotides are synthetic fragments of DNA that can bind to mRNAs, causing them to be cut into pieces.







Intravitreal injection (injection in the eye) of ASOs specifically targeting the mutated Ataxin-7 reduced protein expression in the retina and ameliorated pathology and vision loss in a SCA7 mouse model.


The results suggest that ASOs targeting ATAXIN-7 might be effective in treating retinal degeneration in patients with SCA7.

-----------------------------------------------------------------------------
http://stm.sciencemag.org/content/10/465/eaap8677.short



woensdag 7 november 2018

Sleep apnea in Machado-Joseph disease: a clinical and polysomnographic evaluation

Machado-Joseph disease (MJD) or spinocerebellar ataxia type 3 (SCA3) is the most common type of autosomal dominant spinocerebellar ataxia (SCA). Sleep disorders have been described as frequent non-motor symptoms in MJD, and with marked impairment on quality of life. However, few studies have evaluated the frequency and characteristics of sleep apnea in MJD.

This study analyzed the prevalence of sleep apnea in 47 patients with MJD by using polysomnography. Clinical variables such as age, age at onset of symptoms, duration of symptoms (at time of evaluation), body index mass, ataxia scales severity and CAG repeat length were compared with polysomnographic findings.


Thirty four percent of MJD patients had OSAS, and 42.5% had excessive daytime somnolence. There were no differences considering ataxia severity, CAG repetition length or other clinical variable.

Conclusions


Patients with MJD have high frequency of obstructive sleep apnea, and this sleep disorder is not correlated with ataxia severity, CAG repetition length or other clinical variable.

maandag 5 november 2018






The 2018 Ross Prize in Molecular Medicine will be awarded to Dr. Huda Y. Zoghbi for her research unveiling the genetic and molecular basis of Rett syndrome and spinocerebellar ataxia, enabling novel therapeutic strategies for these devastating diseases. Complemented by fundamental studies in neurodevelopment, Dr. Zoghbi continues to pursue the complex molecular processes driving the pathogenesis of some of the most devastating neurological conditions.


The Ross Prize in Molecular Medicine was established in conjunction with the Feinstein Institute for Medical Research and Molecular Medicine to recognize biomedical scientists whose discoveries transformed the way medicine is practiced. The awardees are midcareer researchers who have made a significant impact in the understanding of human disease pathogenesis and/or treatment. Moreover, it is anticipated that they will continue to make profound advances in the general field of molecular medicine.


On the exact same day in 1993, both Dr. Huda Zoghbi and Dr. Harry Orr independently discovered the mutation responsible for SCA1. But this wasn’t a simple genetic deletion or point mutation. Zoghbi and Orr found that the affected gene, ATXN1, has a repetitive CAG trinucleotide sequence, also known as a polyglutamine tract. They discovered that this region is prone to errors during DNA replication, resulting in expansion of the polyglutamine tract. Healthy patients have ~30 CAG repeats in ATXN1, while SCA1 patients have 40 or more. In families affected with SCA1, the number of CAG repeats increases with each generation, correlating with increased severity and an earlier age of disease onset.


Zoghbi’s lab also found that this altered ATXN1gene sequence encodes a bulky, improperly folded protein that is toxic to brain cells. These studies are relevant to multiple neurodegenerative diseases, including Alzheimer’s disease, which also involves misfolded proteins and neurotoxicity.

------------------------------------------------------------------------------------------







zondag 4 november 2018

Cadent Therapeutics initiates phase 1 clinical study


On March 12, 2018, Cadent Therapeutics, a precision neuroscience company developing novel medicines to restore movement and cognitive function in patients with neurological and psychiatric disease, announced the initiation of a Phase 1 clinical study for its lead product candidate CAD-1883. The compound is a selective first-in-class positive allosteric modulator of the small conductance calcium-activated potassium (SK) channel.

“This is an important step in the development of meaningful new therapies for people with movement disorders,” said Michael Curtis, PhD, President and CEO of Cadent Therapeutics. “We have shown that allosteric modulation of the SK channel restores cadence to neuronal firing and is efficacious in disease models of ataxia and tremor. Our hope is that by precisely tuning dysregulated neuronal firing, we can reduce disability and restore motor function in patients with spinocerebellar ataxia and essential tremor.”

In patients with spinocerebellar ataxia and essential tremor, the firing pattern of neurons in the cerebellum has become dysregulated, resulting in the loss of motor control, impacting mobility and fine motor function. By changing the calcium sensitivity of SK channels, CAD-1883 causes potassium current to flow at lower calcium concentrations, restoring neuronal firing regularity and improving motor function.

------------------------------------------------------------------------------




vrijdag 2 november 2018

Ionis closes strategic collaboration with Biogen to develop drugs for a broad range of neurological diseases


Excerpt from Press release June 5, 2018


Ionis Pharmaceuticals announced today that it closed its expanded strategic collaboration with Biogen to discover and develop novel antisense drugs for a broad range of neurological diseases.


On April 20, 2018, Ionis and Biogen announced they would expand their strategic collaboration to develop novel antisense drugs for a broad range of neurological diseases through a new ten-year collaboration. This collaboration capitalizes on Ionis' leadership in RNA-targeted therapies as well as Ionis and Biogen's joint expertise in neuroscience research and drug development. It builds upon a productive collaboration that produced SPINRAZA® (nusinersen), the first and only approved treatment for patients with spinal muscular atrophy.

The companies plan to advance programs for a broad range of neurological diseases for which few treatment options exist today. Disease areas include dementia, neuromuscular diseases, movement disorders, ophthalmology, diseases of the inner ear, and neuropsychiatry.

Ionis will be responsible for the identification of antisense drug candidates based on selected targets, while Biogen will have the option to license therapies arising out of this collaboration and will be responsible for and pay for non-clinical studies, clinical development, manufacturing, and commercialization. In addition, Biogen may pay milestone payments, license fees and royalties on net sales.

------------------------------------------------------------------------------------
View original content with multimedia







dinsdag 30 oktober 2018

Patients with cerebellar ataxia do not benefit from limb weights




Patients with cerebellar ataxia are sometimes treated by the addition of mass to the limbs, though this practice has received limited study. 


Recent work suggests that adding mass to the limbs might have predictable effects on the pattern of cerebellar dysmetria (i.e., over or undershooting) that depends on a hypothesized mismatch between the actual limb inertia and the brain's estimate of limb inertia. Based on this model, the researchers predicted that addition of mass would only be effective in reducing dysmetria in hypometric patients. 


Cerebellar patients were challenged with making a single-joint, single degree of freedom reaching movement while various limb masses were tested. In this task, some single-jointed reaches were improved by adding masses that were optimized in a patient-specific manner. However, this improvement did not translate to multi-joint movements. In multi-joint movements, the "best" patient-specific masses (as determined in a single-joint task) generally exacerbated subjects' reaching errors. 


This finding raises questions as to the merits of adding limb weights as a therapy to mitigate the effects of dysmetria.

------------------------------------------------------------------------------
Patients with Cerebellar Ataxia Do Not Benefit from Limb Weights, Zimmet, A.M., Cowan, N.J. & Bastian, A.J. Cerebellum (2018). https://doi.org/10.1007/s12311-018-0962-1




vrijdag 3 augustus 2018

Filmpje ataxie


De ataxie commercial "Baby and me" probeert uit te beelden hoe het is om te leven met de aandoening ataxie.

De ontwerpers maken gebruik van schokkende beelden. Ook de muziek helpt mee ataxie uit te leggen.








woensdag 25 april 2018

READISCA is Recruiting for SCA Research



READISCA is recruiting for SCA research in 18 study sites across the US. SCA1 and SCA3 participants are needed!





READISCA is a study to get ready for treatment trials that are anticipated within the next 5 years. The study will aid in clinical trial readiness for SCA1 and SCA3. The study is not a treatment trial.

Who is asked to participate?



  • Individuals with a  clinical or genetic diagnosis of spinocerebellar ataxia type 1 or type 3 (SCA1 or SCA3) 
or

  • Individuals with a first-degree relative that has a diagnosis of SCA1 or SCA3.

Participants should be in early or pre-symptomatic stages of the disease.




Main goals of the study




  • To establish the world’s largest group of early stage and symptomless SCA1 and SCA3 individuals.
  • To validate imaging signs in early stage and symptomless SCA1 and SCA3 individuals.
  • To adapt recent ndings to design clinical trials for spinocerebellar ataxias.


This research visit will likely take about half a day. Participants will be asked to return annually for the next five years


Research visit



We will draw blood and perform DNA testing to confirm the genetic diagnosis. If you wish to know your gene status, we will release the DNA results to your doctor or genetic counselor at no cost to you.
You will be asked about optional spinal fluid collection by spinal tap (you can say “no” but the spinal fluid is extremely important for developing new drugs for SCAs).


If qualified, you will be asked to participate in an imaging study using an MRI machine in Boston, Baltimore, Minneapolis or Gainesville (FL).


There will be no cost for participation, and all expenses will be paid.







maandag 5 maart 2018

Joseph Bartell wrote a book about his life with ataxia



Joseph Bartell is an ataxia patient and wrote a book about his life with ataxia. The title of the book is  "Walking with a cane and half a brain - my journey, living with ataxia".








In the book Joseph describes his life before ataxia, the first signs, the diagnosis,  kids?, treatments, tell others?, why tell them now?, life with ataxia.

You can download the book for free.



---------------------------------------------------------------------------------------

Website Life with ataxia











dinsdag 27 februari 2018

#ShowYourRare Tomorrow to Help Spread Awareness for Rare Diseases









Tomorrow is Rare Disease Day! 7,000+ rare diseases affect 30 million people in the United States - and an estimated 300 million in the world! On February 28, 2018, people affected with rare diseases, such as Ataxia, will come together to raise awareness for all rare diseases.

What?


Rare Disease Day takes place on the last day of February each year. The main objective of Rare Disease Day is to raise awareness amongst the general public and decision-makers about rare diseases and their impact on patients' lives. The campaign targets primarily the general public and also seeks to raise awareness amongst policy makers, public authorities, industry representatives, researchers, health professionals and anyone who has a genuine interest in rare diseases.

Why?


Building awareness of rare diseases is so important because 1 in 20 people will live with a rare disease at some point in their life. Despite this, there is no cure for the majority of rare diseases and many go undiagnosed. Rare Disease Day improves knowledge amongst the general public of rare diseases while encouraging researchers and decision makers to address the needs of those living with rare diseases.

Who?


Rare Disease Day events are down to hundreds of patient organisations all over the world who work on a local and national level to raise awareness for the rare disease community in their countries.

Since Rare Disease Day was first launched by EURORDIS and its Council of National Alliances in 2008, thousands of events have taken place throughout the world reaching hundreds of thousands of people and resulting in a great deal of media coverage. We especially thank our official Rare Disease Day partners, the National Alliances. These are umbrella organisations who group together several rare disease organisations in a given country or region. Click on a logo of one of the National Alliances to go to their website.

Where?


The campaign started as a European event and has progressively become a world phenomenon, with the USA joining in 2009 and participation in 94 countries all over the world in 2017. Hundreds of cities continue to take part in Rare Disease Day and we hope even more will join in 2018.

Some countries have decided to raise rare disease awareness further, for example, Spain declared 2013 as the National Year for Rare Diseases.


When?


The first Rare Disease Day was celebrated in 2008 on 29 February, a ‘rare’ date that happens only once every four years. Ever since then, Rare Disease Day has taken place on the last day of February, a month known for having a ‘rare’ number of days.

On rarediseaseday.org you can find information about the thousands of events happening around the world on the last day of February. If you are planning an event, register your event details on the Post your Event page to get your event listed on the site!

---------------------------------------------------------------------------
Join the Worldwide Social Media Campaign

Want to get involved? Post a photo on social media and include the hashtags #ShowYourRare, #MyRare, or #RareDiseaseDay. Use #Ataxia too! Take it a step further and print this sign to hold up in your photo or paint your face in Rare Disease Day logo colors. (See examples of face paint)









dinsdag 19 december 2017

$1 million grant for ataxia research



A Chapman University School of Pharmacy junior faculty member has been awarded a $1,059,867 grant by the National Institutes of Health (NIH) for ataxia research.


Ataxia is a degenerative, hereditary disease of the nervous system. Those diagnosed often experience the same symptoms as someone who is drunk, such as slurred speech, stumbling and falling. All are related to deterioration of the part of the brain that is responsible for coordinating movement.


The disease can be fatal within 10 to 15 years of the onset of symptoms and can affect people of all ages. There are currently no effective treatments or cure for the estimated 150,000 Americans diagnosed due to the unknown origin and development of the disease.


With this grant, Chapman Assistant Professor in ion channel pharmacology, Miao Zhang, Ph.D., will be able to further their research to develop new drug treatments for movement disorders.





“This innovation award allows us to take further action to identify the underlying causes of ataxia,” Professor Zhang said. “These SK ion channels have been associated with ataxia, although their exact role is not clear. Drugs that enhance SK ion channel activity have shown promise for treatment in past studies.”

---------------------------------------------------------------------------------------------------
 Chapman University December 15, 2017